GleamWall
中文EN

DMAC DiaMedica Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1401040 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-26.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-100.2%
ROA-86.3%
ROIC (approx.)-94.2%
Asset turnover—

Leverage & solvency

Liabilities / assets20.7%
Debt / equity0.00x
Current ratio4.76x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-13.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$24.61M$19.06M$13.11M$7.84M$8.77M
SG&A expense$9.78M$7.62M$8.16M$6.16M$4.88M
Operating income-$34.40M-$26.68M-$21.27M-$14.00M-$13.65M
Pretax income-$32.74M-$24.41M-$19.34M-$13.65M-$13.56M
Income tax$28,000$30,000$43,000$28,000$28,000
Net income-$32.77M-$24.44M-$19.38M-$13.68M-$13.59M
EBITDA-$34.35M-$26.64M-$21.24M-$13.98M-$13.62M
EPS (basic)-0.70-0.60-0.60-0.52-0.65
EPS (diluted)————-0.65
Weighted avg. shares (diluted)————20.77M
Balance sheet
Cash & equivalents$15.65M$3.02M$4.54M$4.73M$4.71M
Short-term investments$44.24M$41.12M$48.35M$28.77M$40.41M
Receivables$258,000$236,000$369,000$82,000$130,000
Current assets$60.63M$44.61M$53.67M$33.84M$45.44M
PP&E, net$145,000$148,000$131,000$136,000$70,000
Total assets$61.37M$46.34M$54.16M$34.40M$45.55M
Current liabilities$5.13M$5.39M$2.79M$2.17M$1.52M
Total liabilities$5.26M$5.63M$3.10M$2.57M$1.53M
Shareholders' equity$56.11M$40.72M$51.06M$31.83M$44.02M
Shares outstanding53.74M42.82M37.96M26.44M26.44M
Cash flow statement
Operating cash flow-$29.06M-$22.08M-$18.73M-$11.51M-$12.25M
Capital expenditure$40,000$25,000$24,000$81,000$22,000
Free cash flow-$29.10M-$22.10M-$18.75M-$11.59M-$12.27M
Investing cash flow-$2.19M$8.56M-$18.30M$11.54M-$20.54M
Financing cash flow$43.88M$11.99M$36.84M-$6,000$30.09M
Depreciation & amortization$43,000$39,000$30,000$25,000$24,000
Stock-based compensation$3.85M$2.08M$1.68M$1.50M$1.56M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.